Ayesha Khalid, MD
Infectious Disease · Jackson, MSNPI 1679702302
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 48 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 40.1% of the total. Reporting peaked in 2019 at $216 and has fallen 81.6% since, to $40 in 2025.
Across 48 payments — averaging $13.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$254
- Smith+Nephew$225
- Paratek Pharmaceuticals, Inc.$50
- Stryker$40
- Merck$37
- Hydrofera LLC$16
- plus $12 from 1 others
What the payments were for
- Food & beverage$633100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $254 |
| Smith+Nephew | 23 | $225 |
| Paratek Pharmaceuticals, Inc. | 3 | $50 |
| Stryker | 1 | $40 |
| Merck | 2 | $37 |
| Hydrofera LLC | 1 | $16 |
| Hollister Incorporated | 1 | $12 |
How this compares
$633 in reported general payments places this provider in the 60th percentile of 36 infectious disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 32 | $10,946 |
| Vancomycin Hcl | 114 | $10,642 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 45 | $8,622 |
| ErtapenemErtapenem Sodium | 15 | $4,526 |
| CeftriaxoneCeftriaxone Sodium | 64 | $4,425 |
| Cefepime Hcl | 23 | $3,805 |
| Meropenem | 28 | $2,974 |
| Sodium Chloride0.9 % Sodium Chloride | 173 | $1,628 |
| Cefazolin Sodium | 36 | $1,296 |
| Ceftazidime | 24 | $1,101 |
| Doxycycline Monohydrate | 41 | $593 |
| Doxycycline Hyclate | 22 | $509 |
| Gentamicin Sulfate | 14 | $336 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $191 |
| Nystatin | 12 | $117 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Jackson
- Jo DealJackson$9K
- Svenja AlbrechtJackson$5K
- Rathel NolanJackson$2K
- Richard FlowersJackson$1K
- Ujjwal DharJackson$1K
- Tulip JhaveriJackson$428
- Prakhar VijayvargiyaJackson$344
- Anne McPhersonJackson$294
- James BrockJackson$270
- Zerelda Esquer GarrigosJackson$214
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.